A Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeated Subcutaneous (SC) Doses of REMD-477 in Subjects With Type 2 Diabetes Mellitus

Trial Profile

A Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeated Subcutaneous (SC) Doses of REMD-477 in Subjects With Type 2 Diabetes Mellitus

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs REMD 477 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors REMD Biotherapeutics
  • Most Recent Events

    • 16 Aug 2016 An additional treatment arm has been added for REMD-477 in Combination with Metformin, Planned number of patients changed from 72 to 102.
    • 16 Aug 2016 Planned End Date changed from 1 Jul 2017 to 1 Nov 2017.
    • 16 Aug 2016 Planned primary completion date changed from 1 May 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top